ID   CBP_HUMAN               Reviewed;        2442 AA.
AC   Q92793; D3DUC9; O00147; Q16376; Q4LE28;
DT   15-JUL-1998, integrated into UniProtKB/Swiss-Prot.
DT   17-OCT-2006, sequence version 3.
DT   10-MAY-2017, entry version 211.
DE   RecName: Full=CREB-binding protein;
DE            EC=2.3.1.48 {ECO:0000269|PubMed:24616510};
GN   Name=CREBBP; Synonyms=CBP;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=9238046; DOI=10.1073/pnas.94.16.8732;
RA   Sobulo O.M., Borrow J., Tomek R., Reshimi S., Harden A.,
RA   Schlegelberger B., Housman D., Doggett N.A., Rowley J.D.,
RA   Zeleznik-Le N.J.;
RT   "MLL is fused to CBP, a histone acetyltransferase, in therapy-related
RT   acute myeloid leukemia with a t(11;16)(q23;p13.3).";
RL   Proc. Natl. Acad. Sci. U.S.A. 94:8732-8737(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=9177780; DOI=10.1006/geno.1997.4699;
RA   Giles R.H., Petrij F., Dauwerse H.G., den Hollander A.I.,
RA   Lushnikova T., van Ommen G.J.B., Goodman R.H., Deaven L.L.,
RA   Doggett N.A., Peters D.J.M., Breuning M.H.;
RT   "Construction of a 1.2-Mb contig surrounding, and molecular analysis
RT   of, the human CREB-binding protein (CBP/CREBBP) gene on chromosome
RT   16p13.3.";
RL   Genomics 42:96-114(1997).
RN   [3]
RP   SEQUENCE REVISION TO 1724-1725; 1789 AND 1812.
RA   Petrij F., den Hollander A.I., Chrivia J.C.;
RL   Submitted (MAR-1999) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Brain;
RA   Nakajima D., Saito K., Yamakawa H., Kikuno R.F., Nakayama M.,
RA   Ohara R., Okazaki N., Koga H., Nagase T., Ohara O.;
RT   "Preparation of a set of expression-ready clones of mammalian long
RT   cDNAs encoding large proteins by the ORF trap cloning method.";
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-405, AND CHROMOSOMAL TRANSLOCATION
RP   WITH KAT6A.
RX   PubMed=8782817; DOI=10.1038/ng0996-33;
RA   Borrow J., Stanton V.P. Jr., Andresen J.M., Becher R., Behm F.G.,
RA   Chaganti R.S.K., Civin C.I., Disteche C., Dube I., Frischauf A.M.,
RA   Horsman D., Mitelman F., Volinia S., Watmore A.E., Housman D.E.;
RT   "The translocation t(8;16)(p11;p13) of acute myeloid leukaemia fuses a
RT   putative acetyltransferase to the CREB-binding protein.";
RL   Nat. Genet. 14:33-41(1996).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-83, AND CHROMOSOMAL TRANSLOCATION WITH
RP   KAT6B.
RX   PubMed=11157802; DOI=10.1093/hmg/10.4.395;
RA   Panagopoulos I., Fioretos T., Isaksson M., Samuelsson U.,
RA   Billstroem R., Stroembeck B., Mitelman F., Johansson B.;
RT   "Fusion of the MORF and CBP genes in acute myeloid leukemia with the
RT   t(10;16)(q22;p13).";
RL   Hum. Mol. Genet. 10:395-404(2001).
RN   [8]
RP   INTERACTION WITH PCAF.
RX   PubMed=8684459; DOI=10.1038/382319a0;
RA   Yang X.-J., Ogryzko V.V., Nishikawa J., Howard B.H., Nakatani Y.;
RT   "A p300/CBP-associated factor that competes with the adenoviral
RT   oncoprotein E1A.";
RL   Nature 382:319-324(1996).
RN   [9]
RP   INTERACTION WITH HIF1A AND EP300.
RX   PubMed=8917528; DOI=10.1073/pnas.93.23.12969;
RA   Arany Z., Huang L.E., Eckner R., Bhattacharya S., Jiang C.,
RA   Goldberg M.A., Bunn H.F., Livingston D.M.;
RT   "An essential role for p300/CBP in the cellular response to hypoxia.";
RL   Proc. Natl. Acad. Sci. U.S.A. 93:12969-12973(1996).
RN   [10]
RP   INTERACTION WITH HTLV-1 TAX.
RX   PubMed=9528808; DOI=10.1128/MCB.18.4.2392;
RA   Bex F., Yin M.-J., Burny A., Gaynor R.B.;
RT   "Differential transcriptional activation by human T-cell leukemia
RT   virus type 1 Tax mutants is mediated by distinct interactions with
RT   CREB binding protein and p300.";
RL   Mol. Cell. Biol. 18:2392-2405(1998).
RN   [11]
RP   INTERACTION WITH KLF1, AND FUNCTION.
RX   PubMed=9707565; DOI=10.1073/pnas.95.17.9855;
RA   Zhang W., Bieker J.J.;
RT   "Acetylation and modulation of erythroid Krueppel-like factor (EKLF)
RT   activity by interaction with histone acetyltransferases.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:9855-9860(1998).
RN   [12]
RP   INTERACTION WITH SRCAP.
RX   PubMed=10347196; DOI=10.1074/jbc.274.23.16370;
RA   Johnston H., Kneer J., Chackalaparampil I., Yaciuk P., Chrivia J.;
RT   "Identification of a novel SNF2/SWI2 protein family member, SRCAP,
RT   which interacts with CREB-binding protein.";
RL   J. Biol. Chem. 274:16370-16376(1999).
RN   [13]
RP   INTERACTION WITH PML.
RX   PubMed=10077561; DOI=10.1073/pnas.96.6.2627;
RA   Doucas V., Tini M., Egan D.A., Evans R.M.;
RT   "Modulation of CREB binding protein function by the promyelocytic
RT   (PML) oncoprotein suggests a role for nuclear bodies in hormone
RT   signaling.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:2627-2632(1999).
RN   [14]
RP   ACETYLATION OF NCOA3.
RX   PubMed=10490106; DOI=10.1016/S0092-8674(00)80054-9;
RA   Chen H., Lin R.J., Xie W., Wilpitz D., Evans R.M.;
RT   "Regulation of hormone-induced histone hyperacetylation and gene
RT   activation via acetylation of an acetylase.";
RL   Cell 98:675-686(1999).
RN   [15]
RP   INTERACTION WITH CITED1.
RX   PubMed=10722728; DOI=10.1074/jbc.275.12.8825;
RA   Yahata T., de Caestecker M.P., Lechleider R.J., Andriole S.,
RA   Roberts A.B., Isselbacher K.J., Shioda T.;
RT   "The MSG1 non-DNA-binding transactivator binds to the p300/CBP
RT   coactivators, enhancing their functional link to the Smad
RT   transcription factors.";
RL   J. Biol. Chem. 275:8825-8834(2000).
RN   [16]
RP   INTERACTION WITH NCOA6.
RX   PubMed=10866662; DOI=10.1128/MCB.20.14.5048-5063.2000;
RA   Mahajan M.A., Samuels H.H.;
RT   "A new family of nuclear receptor coregulators that integrates nuclear
RT   receptor signaling through CBP.";
RL   Mol. Cell. Biol. 20:5048-5063(2000).
RN   [17]
RP   INTERACTION WITH MAFG, AND FUNCTION IN ACETYLATION OF MAFG.
RX   PubMed=11154691; DOI=10.1074/jbc.M007846200;
RA   Hung H.-L., Kim A.Y., Hong W., Rakowski C., Blobel G.A.;
RT   "Stimulation of NF-E2 DNA binding by CREB-binding protein (CBP)-
RT   mediated acetylation.";
RL   J. Biol. Chem. 276:10715-10721(2001).
RN   [18]
RP   INTERACTION WITH NFATC4.
RX   PubMed=11514544; DOI=10.1074/jbc.M102961200;
RA   Yang T.T.C., Davis R.J., Chow C.-W.;
RT   "Requirement of two NFATc4 transactivation domains for CBP
RT   potentiation.";
RL   J. Biol. Chem. 276:39569-39576(2001).
RN   [19]
RP   INTERACTION WITH MECOM.
RX   PubMed=11568182; DOI=10.1074/jbc.M106733200;
RA   Chakraborty S., Senyuk V., Sitailo S., Chi Y., Nucifora G.;
RT   "Interaction of EVI1 with cAMP-responsive element-binding protein-
RT   binding protein (CBP) and p300/CBP-associated factor (P/CAF) results
RT   in reversible acetylation of EVI1 and in co-localization in nuclear
RT   speckles.";
RL   J. Biol. Chem. 276:44936-44943(2001).
RN   [20]
RP   INTERACTION WITH HTLV-1 TAX.
RX   PubMed=11463834; DOI=10.1128/MCB.21.16.5520-5530.2001;
RA   Scoggin K.E.S., Ulloa A., Nyborg J.K.;
RT   "The oncoprotein Tax binds the SRC-1-interacting domain of CBP/p300 to
RT   mediate transcriptional activation.";
RL   Mol. Cell. Biol. 21:5520-5530(2001).
RN   [21]
RP   INTERACTION WITH HTLV-1 ACCESSORY PROTEIN P30II.
RX   PubMed=11559821; DOI=10.1128/JVI.75.20.9885-9895.2001;
RA   Zhang W., Nisbet J.W., Albrecht B., Ding W., Kashanchi F.,
RA   Bartoe J.T., Lairmore M.D.;
RT   "Human T-lymphotropic virus type 1 p30(II) regulates gene
RT   transcription by binding CREB binding protein/p300.";
RL   J. Virol. 75:9885-9895(2001).
RN   [22]
RP   INTERACTION WITH TRERF1.
RX   PubMed=11349124; DOI=10.1074/jbc.M100113200;
RA   Gizard F., Lavallee B., DeWitte F., Hum D.W.;
RT   "A novel zinc finger protein TReP-132 interacts with CBP/p300 to
RT   regulate human CYP11A1 gene expression.";
RL   J. Biol. Chem. 276:33881-33892(2001).
RN   [23]
RP   INTERACTION WITH PELP1.
RX   PubMed=11481323; DOI=10.1074/jbc.M103783200;
RA   Vadlamudi R.K., Wang R.-A., Mazumdar A., Kim Y.-S., Shin J., Sahin A.,
RA   Kumar R.;
RT   "Molecular cloning and characterization of PELP1, a novel human
RT   coregulator of estrogen receptor alpha.";
RL   J. Biol. Chem. 276:38272-38279(2001).
RN   [24]
RP   INTERACTION WITH HHV-8 PROTEIN VIRF1.
RX   PubMed=11314014; DOI=10.1038/sj.onc.1204163;
RA   Lin R., Genin P., Mamane Y., Sgarbanti M., Battistini A.,
RA   Harrington W.J. Jr., Barber G.N., Hiscott J.;
RT   "HHV-8 encoded vIRF-1 represses the interferon antiviral response by
RT   blocking IRF-3 recruitment of the CBP/p300 coactivators.";
RL   Oncogene 20:800-811(2001).
RN   [25]
RP   INTERACTION WITH SPIB.
RX   PubMed=11864910;
RA   Yamamoto H., Kihara-Negishi F., Yamada T., Suzuki M., Nakano T.,
RA   Oikawa T.;
RT   "Interaction between the hematopoietic Ets transcription factor Spi-B
RT   and the coactivator CREB-binding protein associated with negative
RT   cross-talk with c-Myb.";
RL   Cell Growth Differ. 13:69-75(2002).
RN   [26]
RP   INTERACTION WITH CITED4.
RX   PubMed=11744733; DOI=10.1074/jbc.M110850200;
RA   Braganca J., Swingler T., Marques F.I.R., Jones T., Eloranta J.J.,
RA   Hurst H.C., Shioda T., Bhattacharya S.;
RT   "Human CREB-binding protein/p300-interacting transactivator with ED-
RT   rich tail (CITED) 4, a new member of the CITED family, functions as a
RT   co-activator for transcription factor AP-2.";
RL   J. Biol. Chem. 277:8559-8565(2002).
RN   [27]
RP   IDENTIFICATION IN A COMPLEX WITH NCOA2; NCOA3; IKKA; IKKB AND IKBKG.
RX   PubMed=11971985; DOI=10.1128/MCB.22.10.3549-3561.2002;
RA   Wu R.-C., Qin J., Hashimoto Y., Wong J., Xu J., Tsai S.Y., Tsai M.-J.,
RA   O'Malley B.W.;
RT   "Regulation of SRC-3 (pCIP/ACTR/AIB-1/RAC-3/TRAM-1) coactivator
RT   activity by I kappa B kinase.";
RL   Mol. Cell. Biol. 22:3549-3561(2002).
RN   [28]
RP   INTERACTION WITH IRF2, AND FUNCTION IN ACETYLATION OF IRF2.
RX   PubMed=12738767; DOI=10.1074/jbc.M213037200;
RA   Masumi A., Yamakawa Y., Fukazawa H., Ozato K., Komuro K.;
RT   "Interferon regulatory factor-2 regulates cell growth through its
RT   acetylation.";
RL   J. Biol. Chem. 278:25401-25407(2003).
RN   [29]
RP   INTERACTION WITH N4BP2.
RX   PubMed=12730195; DOI=10.1074/jbc.M303518200;
RA   Watanabe N., Wachi S., Fujita T.;
RT   "Identification and characterization of BCL-3-binding protein:
RT   implications for transcription and DNA repair or recombination.";
RL   J. Biol. Chem. 278:26102-26110(2003).
RN   [30]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=12929931; DOI=10.1359/jbmr.2003.18.8.1419;
RA   Iioka T., Furukawa K., Yamaguchi A., Shindo H., Yamashita S.,
RA   Tsukazaki T.;
RT   "P300/CBP acts as a coactivator to cartilage homeoprotein-1 (Cart1),
RT   paired-like homeoprotein, through acetylation of the conserved lysine
RT   residue adjacent to the homeodomain.";
RL   J. Bone Miner. Res. 18:1419-1429(2003).
RN   [31]
RP   FUNCTION, AND INTERACTION WITH NPAS2 AND CLOCK.
RX   PubMed=14645221; DOI=10.1074/jbc.M311973200;
RA   Curtis A.M., Seo S.B., Westgate E.J., Rudic R.D., Smyth E.M.,
RA   Chakravarti D., FitzGerald G.A., McNamara P.;
RT   "Histone acetyltransferase-dependent chromatin remodeling and the
RT   vascular clock.";
RL   J. Biol. Chem. 279:7091-7097(2004).
RN   [32]
RP   INTERACTION WITH ELF3.
RX   PubMed=15075319; DOI=10.1074/jbc.M401356200;
RA   Wang H., Fang R., Cho J.-Y., Libermann T.A., Oettgen P.;
RT   "Positive and negative modulation of the transcriptional activity of
RT   the ETS factor ESE-1 through interaction with p300, CREB-binding
RT   protein, and Ku 70/86.";
RL   J. Biol. Chem. 279:25241-25250(2004).
RN   [33]
RP   INTERACTION WITH MLLT7.
RX   PubMed=15126506; DOI=10.1074/jbc.M401138200;
RA   van der Horst A., Tertoolen L.G.J., de Vries-Smits L.M.M., Frye R.A.,
RA   Medema R.H., Burgering B.M.T.;
RT   "FOXO4 is acetylated upon peroxide stress and deacetylated by the
RT   longevity protein hSir2(SIRT1).";
RL   J. Biol. Chem. 279:28873-28879(2004).
RN   [34]
RP   SUBCELLULAR LOCATION.
RX   PubMed=15488321; DOI=10.1016/j.neulet.2004.08.062;
RA   Pradhan A., Liu Y.;
RT   "The calcium-responsive transactivator recruits CREB binding protein
RT   to nuclear bodies.";
RL   Neurosci. Lett. 370:191-195(2004).
RN   [35]
RP   INTERACTION WITH FOXO1.
RX   PubMed=15220471; DOI=10.1073/pnas.0400593101;
RA   Daitoku H., Hatta M., Matsuzaki H., Aratani S., Ohshima T.,
RA   Miyagishi M., Nakajima T., Fukamizu A.;
RT   "Silent information regulator 2 potentiates Foxo1-mediated
RT   transcription through its deacetylase activity.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:10042-10047(2004).
RN   [36]
RP   INTERACTION WITH SS18L1/CREST.
RX   PubMed=14716005; DOI=10.1126/science.1089845;
RA   Aizawa H., Hu S.-C., Bobb K., Balakrishnan K., Ince G., Gurevich I.,
RA   Cowan M., Ghosh A.;
RT   "Dendrite development regulated by CREST, a calcium-regulated
RT   transcriptional activator.";
RL   Science 303:197-202(2004).
RN   [37]
RP   PHOSPHORYLATION AT SER-1382 AND SER-1386 BY CHUK/IKKA.
RX   PubMed=17434128; DOI=10.1016/j.molcel.2007.02.019;
RA   Huang W.C., Ju T.K., Hung M.C., Chen C.C.;
RT   "Phosphorylation of CBP by IKKalpha promotes cell growth by switching
RT   the binding preference of CBP from p53 to NF-kappaB.";
RL   Mol. Cell 26:75-87(2007).
RN   [38]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1030, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Embryonic kidney;
RX   PubMed=17525332; DOI=10.1126/science.1140321;
RA   Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III,
RA   Hurov K.E., Luo J., Bakalarski C.E., Zhao Z., Solimini N.,
RA   Lerenthal Y., Shiloh Y., Gygi S.P., Elledge S.J.;
RT   "ATM and ATR substrate analysis reveals extensive protein networks
RT   responsive to DNA damage.";
RL   Science 316:1160-1166(2007).
RN   [39]
RP   INTERACTION WITH MTDH.
RX   PubMed=18316612; DOI=10.1158/0008-5472.CAN-07-6164;
RA   Sarkar D., Park E.S., Emdad L., Lee S.-G., Su Z.-Z., Fisher P.B.;
RT   "Molecular basis of nuclear factor-kappaB activation by astrocyte
RT   elevated gene-1.";
RL   Cancer Res. 68:1478-1484(2008).
RN   [40]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-121; SER-2063; SER-2076
RP   AND SER-2079, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [41]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [42]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2063, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [43]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-1014; LYS-1216; LYS-1583;
RP   LYS-1591; LYS-1592; LYS-1595; LYS-1597; LYS-1741 AND LYS-1744, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [44]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-121, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [45]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [46]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E.,
RA   Timmerman E., Prieto J., Arnesen T., Sherman F., Gevaert K.,
RA   Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-
RT   terminal acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [47]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1076; SER-1763 AND
RP   SER-2063, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [48]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [49]
RP   METHYLATION [LARGE SCALE ANALYSIS] AT ARG-220, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Colon carcinoma;
RX   PubMed=24129315; DOI=10.1074/mcp.O113.027870;
RA   Guo A., Gu H., Zhou J., Mulhern D., Wang Y., Lee K.A., Yang V.,
RA   Aguiar M., Kornhauser J., Jia X., Ren J., Beausoleil S.A., Silva J.C.,
RA   Vemulapalli V., Bedford M.T., Comb M.J.;
RT   "Immunoaffinity enrichment and mass spectrometry analysis of protein
RT   methylation.";
RL   Mol. Cell. Proteomics 13:372-387(2014).
RN   [50]
RP   FUNCTION AS ACETYLTRANSFERASE OF PCNA, AND INTERACTION WITH PCNA.
RX   PubMed=24939902; DOI=10.1093/nar/gku533;
RA   Cazzalini O., Sommatis S., Tillhon M., Dutto I., Bachi A., Rapp A.,
RA   Nardo T., Scovassi A.I., Necchi D., Cardoso M.C., Stivala L.A.,
RA   Prosperi E.;
RT   "CBP and p300 acetylate PCNA to link its degradation with nucleotide
RT   excision repair synthesis.";
RL   Nucleic Acids Res. 42:8433-8448(2014).
RN   [51]
RP   STRUCTURE BY NMR OF 345-439 IN COMPLEX WITH 776-826 OF HIF1A.
RX   PubMed=11959977; DOI=10.1073/pnas.082121399;
RA   Dames S.A., Martinez-Yamout M., De Guzman R.N., Dyson H.J.,
RA   Wright P.E.;
RT   "Structural basis for Hif-1 alpha /CBP recognition in the cellular
RT   hypoxic response.";
RL   Proc. Natl. Acad. Sci. U.S.A. 99:5271-5276(2002).
RN   [52]
RP   CHROMOSOMAL TRANSLOCATION WITH KAT6A.
RX   PubMed=11742995; DOI=10.1093/emboj/20.24.7184;
RA   Kitabayashi I., Aikawa Y., Nguyen L.A., Yokoyama A., Ohki M.;
RT   "Activation of AML1-mediated transcription by MOZ and inhibition by
RT   the MOZ-CBP fusion protein.";
RL   EMBO J. 20:7184-7196(2001).
RN   [53]
RP   STRUCTURE BY NMR OF 589-679 IN COMPLEX WITH HIV-1 TAT.
RX   PubMed=14744133; DOI=10.1021/bi035612l;
RA   Vendel A.C., Lumb K.J.;
RT   "NMR mapping of the HIV-1 Tat interaction surface of the KIX domain of
RT   the human coactivator CBP.";
RL   Biochemistry 43:904-908(2004).
RN   [54]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 1081-1197.
RX   PubMed=22464331; DOI=10.1016/j.cell.2012.02.013;
RA   Filippakopoulos P., Picaud S., Mangos M., Keates T., Lambert J.P.,
RA   Barsyte-Lovejoy D., Felletar I., Volkmer R., Muller S., Pawson T.,
RA   Gingras A.C., Arrowsmith C.H., Knapp S.;
RT   "Histone recognition and large-scale structural analysis of the human
RT   bromodomain family.";
RL   Cell 149:214-231(2012).
RN   [55]
RP   X-RAY CRYSTALLOGRAPHY (1.40 ANGSTROMS) OF 1082-1197, FUNCTION,
RP   INTERACTION WITH ASF1A; ASF1B; ACETYLATED HISTONES AND TP53,
RP   MUTAGENESIS OF ASP-1116; PHE-1126; ASN-1162; TRP-1165; SER-1179;
RP   LYS-1180 AND GLU-1183, CHARACTERIZATION OF VARIANT RSTS1 CYS-1175,
RP   CATALYTIC ACTIVITY, AND AUTOACETYLATION.
RX   PubMed=24616510; DOI=10.1073/pnas.1319122111;
RA   Das C., Roy S., Namjoshi S., Malarkey C.S., Jones D.N.,
RA   Kutateladze T.G., Churchill M.E., Tyler J.K.;
RT   "Binding of the histone chaperone ASF1 to the CBP bromodomain promotes
RT   histone acetylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 111:E1072-E1081(2014).
RN   [56]
RP   X-RAY CRYSTALLOGRAPHY (1.83 ANGSTROMS) OF 1080-1316 IN COMPLEX WITH
RP   ZINC.
RX   PubMed=24361270; DOI=10.1016/j.str.2013.10.021;
RA   Plotnikov A.N., Yang S., Zhou T.J., Rusinova E., Frasca A., Zhou M.M.;
RT   "Structural insights into acetylated-histone H4 recognition by the
RT   bromodomain-PHD finger module of human transcriptional coactivator
RT   CBP.";
RL   Structure 22:353-360(2014).
RN   [57]
RP   VARIANT RSTS1 PRO-1378.
RX   PubMed=11331617; DOI=10.1093/hmg/10.10.1071;
RA   Murata T., Kurokawa R., Krones A., Tatsumi K., Ishii M., Taki T.,
RA   Masuno M., Ohashi H., Yanagisawa M., Rosenfeld M.G., Glass C.K.,
RA   Hayashi Y.;
RT   "Defect of histone acetyltransferase activity of the nuclear
RT   transcriptional coactivator CBP in Rubinstein-Taybi syndrome.";
RL   Hum. Mol. Genet. 10:1071-1076(2001).
RN   [58]
RP   VARIANT RSTS1 CYS-1175.
RX   PubMed=12114483; DOI=10.1136/jmg.39.7.496;
RA   Bartsch O., Locher K., Meinecke P., Kress W., Seemanova E., Wagner A.,
RA   Ostermann K., Roedel G.;
RT   "Molecular studies in 10 cases of Rubinstein-Taybi syndrome, including
RT   a mild variant showing a missense mutation in codon 1175 of CREBBP.";
RL   J. Med. Genet. 39:496-501(2002).
RN   [59]
RP   VARIANTS RSTS1 LYS-1278 AND HIS-1664, AND CHARACTERIZATION OF VARIANTS
RP   RSTS1 LYS-1278 AND HIS-1664.
RX   PubMed=12566391; DOI=10.1093/hmg/ddg039;
RA   Kalkhoven E., Roelfsema J.H., Teunissen H., den Boer A., Ariyuerek Y.,
RA   Zantema A., Breuning M.H., Hennekam R.C.M., Peters D.J.M.;
RT   "Loss of CBP acetyltransferase activity by PHD finger mutations in
RT   Rubinstein-Taybi syndrome.";
RL   Hum. Mol. Genet. 12:441-450(2003).
RN   [60]
RP   VARIANTS RSTS1 LYS-1278; ILE-1447; HIS-1450; ARG-1470 AND HIS-1664.
RX   PubMed=15706485; DOI=10.1086/429130;
RA   Roelfsema J.H., White S.J., Ariyuerek Y., Bartholdi D., Niedrist D.,
RA   Papadia F., Bacino C.A., den Dunnen J.T., van Ommen G.-J.B.,
RA   Breuning M.H., Hennekam R.C., Peters D.J.M.;
RT   "Genetic heterogeneity in Rubinstein-Taybi syndrome: mutations in both
RT   the CBP and EP300 genes cause disease.";
RL   Am. J. Hum. Genet. 76:572-580(2005).
RN   [61]
RP   VARIANT RSTS1 ALA-910.
RX   PubMed=20684013; DOI=10.1002/ajmg.a.33598;
RA   Bartsch O., Kress W., Kempf O., Lechno S., Haaf T., Zechner U.;
RT   "Inheritance and variable expression in Rubinstein-Taybi syndrome.";
RL   Am. J. Med. Genet. A 152A:2254-2261(2010).
RN   [62]
RP   VARIANTS HIS-503; THR-532 AND ASN-546, AND VARIANTS RSTS1 PHE-650;
RP   THR-789; CYS-1175; ALA-1278; PRO-1378; TYR-1406; PRO-1415; THR-1475;
RP   PHE-1503; PRO-1507 AND ASN-1543.
RX   PubMed=25388907; DOI=10.1111/cge.12537;
RA   Spena S., Milani D., Rusconi D., Negri G., Colapietro P., Elcioglu N.,
RA   Bedeschi F., Pilotta A., Spaccini L., Ficcadenti A., Magnani C.,
RA   Scarano G., Selicorni A., Larizza L., Gervasini C.;
RT   "Insights into genotype-phenotype correlations from CREBBP point
RT   mutation screening in a cohort of 46 Rubinstein-Taybi syndrome
RT   patients.";
RL   Clin. Genet. 88:431-440(2015).
CC   -!- FUNCTION: Acetylates histones, giving a specific tag for
CC       transcriptional activation. Also acetylates non-histone proteins,
CC       like NCOA3 and FOXO1. Binds specifically to phosphorylated CREB
CC       and enhances its transcriptional activity toward cAMP-responsive
CC       genes. Acts as a coactivator of ALX1. Acts as a circadian
CC       transcriptional coactivator which enhances the activity of the
CC       circadian transcriptional activators: NPAS2-ARNTL/BMAL1 and CLOCK-
CC       ARNTL/BMAL1 heterodimers. Acetylates PCNA; acetylation promotes
CC       removal of chromatin-bound PCNA and its degradation during
CC       nucleotide excision repair (NER) (PubMed:24939902).
CC       {ECO:0000269|PubMed:11154691, ECO:0000269|PubMed:12738767,
CC       ECO:0000269|PubMed:12929931, ECO:0000269|PubMed:14645221,
CC       ECO:0000269|PubMed:24939902, ECO:0000269|PubMed:9707565}.
CC   -!- CATALYTIC ACTIVITY: Acetyl-CoA + [protein]-L-lysine = CoA +
CC       [protein]-N(6)-acetyl-L-lysine. {ECO:0000269|PubMed:24616510}.
CC   -!- SUBUNIT: Found in a complex containing NCOA2; NCOA3; IKKA; IKKB
CC       and IKBKG. Probably part of a complex with HIF1A and EP300.
CC       Interacts with GATA1; the interaction results in acetylation and
CC       enhancement of transcriptional activity of GATA1. Interacts with
CC       MAF AND ZCCHC12. Interacts with DAXX; the interaction is dependent
CC       on CBP sumoylation and results in suppression of the
CC       transcriptional activity via recruitment of HDAC2 to DAXX (By
CC       similarity). Interacts with phosphorylated CREB1. Interacts with
CC       CITED4 (C-terminal region). Interacts (via the TAZ-type 1 domain)
CC       with HIF1A. Interacts with SRCAP, CARM1, ELF3, MLLT7/FOXO4, N4BP2,
CC       NCOA1, NCOA3, NCOA6, PCAF, DDX5, DDX17, PELP1, PML, SMAD1, SMAD2,
CC       SMAD3, SPIB and TRERF1. Interacts with HTLV-1 Tax and p30II.
CC       Interacts with HIV-1 Tat. Interacts with KLF1; the interaction
CC       results in acetylation of KLF1 and enhancement of its
CC       transcriptional activity. Interacts with MTDH. Interacts with
CC       NFATC4. Interacts with MAFG; the interaction acetylates MAFG in
CC       the basic region and stimulates NFE2 transcriptional activity
CC       through increasing its DNA-binding activity. Interacts with IRF2;
CC       the interaction acetylates IRF2 and regulates its activity on the
CC       H4 promoter. Interacts (via N-terminus) with SS18L1/CREST (via C-
CC       terminus). Interacts with MECOM. Interacts with CITED1 (via C-
CC       terminus). Interacts with FOXO1; the interaction acetylates FOXO1
CC       and inhibits its transcriptional activity. Interacts with human
CC       herpes virus 8/HHV-8 protein vIRF-1; this interaction inhibits
CC       CREBBP binding to IRF3. Interacts with NPAS2, CLOCK and
CC       ARNTL/BMAL1. Interacts with ASF1A and ASF1B; this promotes histone
CC       acetylation. Interacts with acetylated TP53/p53 and with the
CC       acetylated histones H3 and H4. Interacts (via transactivation
CC       domain and C-terminus) with PCNA; the interaction occurs on
CC       chromatin in UV-irradiated damaged cells (PubMed:24939902).
CC       {ECO:0000250, ECO:0000269|PubMed:10077561,
CC       ECO:0000269|PubMed:10347196, ECO:0000269|PubMed:10722728,
CC       ECO:0000269|PubMed:10866662, ECO:0000269|PubMed:11154691,
CC       ECO:0000269|PubMed:11314014, ECO:0000269|PubMed:11349124,
CC       ECO:0000269|PubMed:11463834, ECO:0000269|PubMed:11481323,
CC       ECO:0000269|PubMed:11514544, ECO:0000269|PubMed:11559821,
CC       ECO:0000269|PubMed:11568182, ECO:0000269|PubMed:11744733,
CC       ECO:0000269|PubMed:11864910, ECO:0000269|PubMed:11959977,
CC       ECO:0000269|PubMed:11971985, ECO:0000269|PubMed:12730195,
CC       ECO:0000269|PubMed:12738767, ECO:0000269|PubMed:14645221,
CC       ECO:0000269|PubMed:14716005, ECO:0000269|PubMed:14744133,
CC       ECO:0000269|PubMed:15075319, ECO:0000269|PubMed:15126506,
CC       ECO:0000269|PubMed:15220471, ECO:0000269|PubMed:18316612,
CC       ECO:0000269|PubMed:24616510, ECO:0000269|PubMed:24939902,
CC       ECO:0000269|PubMed:8684459, ECO:0000269|PubMed:8917528,
CC       ECO:0000269|PubMed:9528808, ECO:0000269|PubMed:9707565}.
CC   -!- INTERACTION:
CC       P03070:- (xeno); NbExp=2; IntAct=EBI-81215, EBI-617698;
CC       P03255:- (xeno); NbExp=3; IntAct=EBI-81215, EBI-2603114;
CC       P03259:- (xeno); NbExp=5; IntAct=EBI-81215, EBI-6947456;
CC       P03259-2:- (xeno); NbExp=3; IntAct=EBI-81215, EBI-7225021;
CC       P31749:AKT1; NbExp=3; IntAct=EBI-81215, EBI-296087;
CC       P10275:AR; NbExp=2; IntAct=EBI-81215, EBI-608057;
CC       P61201:COPS2; NbExp=3; IntAct=EBI-81215, EBI-1050386;
CC       P16220:CREB1; NbExp=2; IntAct=EBI-81215, EBI-711855;
CC       P35222:CTNNB1; NbExp=2; IntAct=EBI-81215, EBI-491549;
CC       Q9UER7:DAXX; NbExp=2; IntAct=EBI-81215, EBI-77321;
CC       Q12778:FOXO1; NbExp=3; IntAct=EBI-81215, EBI-1108782;
CC       O43524:FOXO3; NbExp=3; IntAct=EBI-81215, EBI-1644164;
CC       Q16665:HIF1A; NbExp=2; IntAct=EBI-81215, EBI-447269;
CC       P42858:HTT; NbExp=2; IntAct=EBI-81215, EBI-466029;
CC       P48551:IFNAR2; NbExp=4; IntAct=EBI-81215, EBI-958408;
CC       O14920:IKBKB; NbExp=2; IntAct=EBI-81215, EBI-81266;
CC       Q14653:IRF3; NbExp=4; IntAct=EBI-81215, EBI-2650369;
CC       Q92831:KAT2B; NbExp=4; IntAct=EBI-81215, EBI-477430;
CC       Q86UE4:MTDH; NbExp=2; IntAct=EBI-81215, EBI-1046588;
CC       P55209:NAP1L1; NbExp=3; IntAct=EBI-81215, EBI-356392;
CC       Q14686:NCOA6; NbExp=2; IntAct=EBI-81215, EBI-78670;
CC       Q04206:RELA; NbExp=5; IntAct=EBI-81215, EBI-73886;
CC       O95863:SNAI1; NbExp=9; IntAct=EBI-81215, EBI-1045459;
CC       P04608:tat (xeno); NbExp=2; IntAct=EBI-81215, EBI-6164389;
CC       P04637:TP53; NbExp=9; IntAct=EBI-81215, EBI-366083;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Note=Recruited to
CC       nuclear bodies by SS18L1/CREST. In the presence of ALX1
CC       relocalizes from the cytoplasm to the nucleus.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q92793-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q92793-2; Sequence=VSP_045700;
CC         Note=No experimental confirmation available.;
CC   -!- DOMAIN: The KIX domain mediates binding to HIV-1 Tat.
CC   -!- PTM: Methylation of the KIX domain by CARM1 blocks association
CC       with CREB. This results in the blockade of CREB signaling, and in
CC       activation of apoptotic response (By similarity). {ECO:0000250}.
CC   -!- PTM: Phosphorylated by CHUK/IKKA at Ser-1382 and Ser-1386; these
CC       phosphorylations promote cell growth by switching the binding
CC       preference of CREBBP from TP53 to NF-kappa-B.
CC       {ECO:0000269|PubMed:17434128}.
CC   -!- PTM: Sumoylation negatively regulates transcriptional activity via
CC       the recruitment of DAAX. {ECO:0000250}.
CC   -!- PTM: Autoacetylation is required for binding to protein
CC       substrates, such as acetylated histones and acetylated TP53/p53.
CC       {ECO:0000269|PubMed:24616510}.
CC   -!- DISEASE: Note=Chromosomal aberrations involving CREBBP may be a
CC       cause of acute myeloid leukemias. Translocation t(8;16)(p11;p13)
CC       with KAT6A; translocation t(11;16)(q23;p13.3) with KMT2A/MLL1;
CC       translocation t(10;16)(q22;p13) with KAT6B. KAT6A-CREBBP may
CC       induce leukemia by inhibiting RUNX1-mediated transcription.
CC   -!- DISEASE: Rubinstein-Taybi syndrome 1 (RSTS1) [MIM:180849]: A
CC       disorder characterized by craniofacial abnormalities, postnatal
CC       growth deficiency, broad thumbs, broad big toes, mental
CC       retardation and a propensity for development of malignancies.
CC       {ECO:0000269|PubMed:11331617, ECO:0000269|PubMed:12114483,
CC       ECO:0000269|PubMed:12566391, ECO:0000269|PubMed:15706485,
CC       ECO:0000269|PubMed:20684013, ECO:0000269|PubMed:24616510,
CC       ECO:0000269|PubMed:25388907}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAE06125.1; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/CBPID42.html";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=P300/CBP entry;
CC       URL="https://en.wikipedia.org/wiki/P300/CBP";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U85962; AAC51331.2; -; mRNA.
DR   EMBL; U89354; AAC51339.1; -; mRNA.
DR   EMBL; U89355; AAC51340.1; -; mRNA.
DR   EMBL; U47741; AAC51770.1; -; mRNA.
DR   EMBL; AB210043; BAE06125.1; ALT_INIT; mRNA.
DR   EMBL; CH471112; EAW85335.1; -; Genomic_DNA.
DR   EMBL; CH471112; EAW85336.1; -; Genomic_DNA.
DR   EMBL; CH471112; EAW85337.1; -; Genomic_DNA.
DR   CCDS; CCDS10509.1; -. [Q92793-1]
DR   CCDS; CCDS45399.1; -. [Q92793-2]
DR   PIR; S39162; S39162.
DR   RefSeq; NP_001073315.1; NM_001079846.1. [Q92793-2]
DR   RefSeq; NP_004371.2; NM_004380.2. [Q92793-1]
DR   UniGene; Hs.459759; -.
DR   PDB; 1JSP; NMR; -; B=1081-1197.
DR   PDB; 1LIQ; NMR; -; A=376-402.
DR   PDB; 1RDT; X-ray; 2.40 A; E=58-80.
DR   PDB; 1WO3; NMR; -; A=387-398.
DR   PDB; 1WO4; NMR; -; A=387-398.
DR   PDB; 1WO5; NMR; -; A=387-398.
DR   PDB; 1WO6; NMR; -; A=376-400.
DR   PDB; 1WO7; NMR; -; A=376-400.
DR   PDB; 1ZOQ; X-ray; 2.37 A; C/D=2065-2111.
DR   PDB; 2D82; NMR; -; A=1081-1197.
DR   PDB; 2KJE; NMR; -; A=1763-1854.
DR   PDB; 2KWF; NMR; -; A=587-673.
DR   PDB; 2L84; NMR; -; A=1081-1197.
DR   PDB; 2L85; NMR; -; A=1081-1197.
DR   PDB; 2LXS; NMR; -; A=587-673.
DR   PDB; 2LXT; NMR; -; A=587-673.
DR   PDB; 2N1A; NMR; -; B=1699-1751.
DR   PDB; 2RNY; NMR; -; A=1081-1197.
DR   PDB; 3DWY; X-ray; 1.98 A; A/B=1081-1197.
DR   PDB; 3P1C; X-ray; 1.82 A; A/B=1081-1197.
DR   PDB; 3P1D; X-ray; 1.86 A; A/B=1081-1197.
DR   PDB; 3P1E; X-ray; 1.80 A; A/B=1081-1197.
DR   PDB; 3P1F; X-ray; 1.63 A; A/B=1081-1197.
DR   PDB; 3SVH; X-ray; 1.80 A; A/B=1081-1197.
DR   PDB; 4A9K; X-ray; 1.81 A; A/B=1081-1197.
DR   PDB; 4N3W; X-ray; 1.90 A; A=1080-1316.
DR   PDB; 4N4F; X-ray; 1.83 A; A=1080-1316.
DR   PDB; 4NR4; X-ray; 1.69 A; A/B=1081-1197.
DR   PDB; 4NR5; X-ray; 1.66 A; A=1081-1197.
DR   PDB; 4NR6; X-ray; 1.66 A; A=1081-1197.
DR   PDB; 4NR7; X-ray; 1.20 A; A=1081-1197.
DR   PDB; 4NYV; X-ray; 1.83 A; A/B/C/D=1081-1197.
DR   PDB; 4NYW; X-ray; 1.43 A; A=1081-1197.
DR   PDB; 4NYX; X-ray; 1.10 A; A=1081-1197.
DR   PDB; 4OUF; X-ray; 1.40 A; A/B=1082-1197.
DR   PDB; 4TQN; X-ray; 1.70 A; A=1081-1197.
DR   PDB; 4TS8; X-ray; 2.00 A; A=1081-1197.
DR   PDB; 4WHU; X-ray; 2.11 A; A=1081-1197.
DR   PDB; 4YK0; X-ray; 1.65 A; A/B/C/D=1083-1196.
DR   PDB; 5CGP; X-ray; 1.96 A; A=1081-1197.
DR   PDB; 5DBM; X-ray; 1.86 A; A/B/C=1082-1197.
DR   PDB; 5EIC; X-ray; 1.50 A; A/B=1081-1197.
DR   PDB; 5ENG; X-ray; 1.30 A; A=1081-1197.
DR   PDB; 5EP7; X-ray; 1.20 A; A=1081-1197.
DR   PDB; 5H85; X-ray; 1.70 A; A=1081-1197.
DR   PDB; 5I83; X-ray; 1.35 A; A=1082-1197.
DR   PDB; 5I86; X-ray; 1.05 A; A/B=1082-1197.
DR   PDB; 5I89; X-ray; 1.07 A; A=1082-1197.
DR   PDB; 5I8B; X-ray; 1.52 A; A=1081-1312.
DR   PDB; 5I8G; X-ray; 1.41 A; A=1081-1312.
DR   PDB; 5J0D; X-ray; 1.05 A; A=1081-1197.
DR   PDB; 5JEM; X-ray; 2.50 A; C/D/F/H=2065-2111.
DR   PDB; 5KTU; X-ray; 1.38 A; A/B=1082-1197.
DR   PDB; 5KTW; X-ray; 1.09 A; A/B/C=1085-1194.
DR   PDB; 5KTX; X-ray; 1.27 A; A=1085-1194.
DR   PDB; 5TB6; X-ray; 1.79 A; A=1081-1197.
DR   PDBsum; 1JSP; -.
DR   PDBsum; 1LIQ; -.
DR   PDBsum; 1RDT; -.
DR   PDBsum; 1WO3; -.
DR   PDBsum; 1WO4; -.
DR   PDBsum; 1WO5; -.
DR   PDBsum; 1WO6; -.
DR   PDBsum; 1WO7; -.
DR   PDBsum; 1ZOQ; -.
DR   PDBsum; 2D82; -.
DR   PDBsum; 2KJE; -.
DR   PDBsum; 2KWF; -.
DR   PDBsum; 2L84; -.
DR   PDBsum; 2L85; -.
DR   PDBsum; 2LXS; -.
DR   PDBsum; 2LXT; -.
DR   PDBsum; 2N1A; -.
DR   PDBsum; 2RNY; -.
DR   PDBsum; 3DWY; -.
DR   PDBsum; 3P1C; -.
DR   PDBsum; 3P1D; -.
DR   PDBsum; 3P1E; -.
DR   PDBsum; 3P1F; -.
DR   PDBsum; 3SVH; -.
DR   PDBsum; 4A9K; -.
DR   PDBsum; 4N3W; -.
DR   PDBsum; 4N4F; -.
DR   PDBsum; 4NR4; -.
DR   PDBsum; 4NR5; -.
DR   PDBsum; 4NR6; -.
DR   PDBsum; 4NR7; -.
DR   PDBsum; 4NYV; -.
DR   PDBsum; 4NYW; -.
DR   PDBsum; 4NYX; -.
DR   PDBsum; 4OUF; -.
DR   PDBsum; 4TQN; -.
DR   PDBsum; 4TS8; -.
DR   PDBsum; 4WHU; -.
DR   PDBsum; 4YK0; -.
DR   PDBsum; 5CGP; -.
DR   PDBsum; 5DBM; -.
DR   PDBsum; 5EIC; -.
DR   PDBsum; 5ENG; -.
DR   PDBsum; 5EP7; -.
DR   PDBsum; 5H85; -.
DR   PDBsum; 5I83; -.
DR   PDBsum; 5I86; -.
DR   PDBsum; 5I89; -.
DR   PDBsum; 5I8B; -.
DR   PDBsum; 5I8G; -.
DR   PDBsum; 5J0D; -.
DR   PDBsum; 5JEM; -.
DR   PDBsum; 5KTU; -.
DR   PDBsum; 5KTW; -.
DR   PDBsum; 5KTX; -.
DR   PDBsum; 5TB6; -.
DR   ProteinModelPortal; Q92793; -.
DR   SMR; Q92793; -.
DR   BioGrid; 107777; 313.
DR   DIP; DIP-952N; -.
DR   IntAct; Q92793; 71.
DR   MINT; MINT-104685; -.
DR   STRING; 9606.ENSP00000262367; -.
DR   BindingDB; Q92793; -.
DR   ChEMBL; CHEMBL5747; -.
DR   GuidetoPHARMACOLOGY; 2734; -.
DR   iPTMnet; Q92793; -.
DR   PhosphoSitePlus; Q92793; -.
DR   BioMuta; CREBBP; -.
DR   DMDM; 116241283; -.
DR   EPD; Q92793; -.
DR   MaxQB; Q92793; -.
DR   PaxDb; Q92793; -.
DR   PeptideAtlas; Q92793; -.
DR   PRIDE; Q92793; -.
DR   Ensembl; ENST00000262367; ENSP00000262367; ENSG00000005339. [Q92793-1]
DR   Ensembl; ENST00000382070; ENSP00000371502; ENSG00000005339. [Q92793-2]
DR   GeneID; 1387; -.
DR   KEGG; hsa:1387; -.
DR   UCSC; uc002cvv.4; human. [Q92793-1]
DR   CTD; 1387; -.
DR   DisGeNET; 1387; -.
DR   GeneCards; CREBBP; -.
DR   GeneReviews; CREBBP; -.
DR   HGNC; HGNC:2348; CREBBP.
DR   HPA; CAB004212; -.
DR   HPA; HPA055861; -.
DR   MalaCards; CREBBP; -.
DR   MIM; 180849; phenotype.
DR   MIM; 600140; gene.
DR   neXtProt; NX_Q92793; -.
DR   OpenTargets; ENSG00000005339; -.
DR   Orphanet; 370026; Acute myeloid leukemia with t(8;16)(p11;p13) translocation.
DR   Orphanet; 353281; Rubinstein-Taybi syndrome due to 16p13.3 microdeletion.
DR   Orphanet; 353277; Rubinstein-Taybi syndrome due to CREBBP mutations.
DR   PharmGKB; PA26866; -.
DR   eggNOG; KOG1778; Eukaryota.
DR   eggNOG; COG5076; LUCA.
DR   GeneTree; ENSGT00760000119206; -.
DR   HOGENOM; HOG000111353; -.
DR   HOVERGEN; HBG000185; -.
DR   InParanoid; Q92793; -.
DR   KO; K04498; -.
DR   OMA; GMNSFNP; -.
DR   OrthoDB; EOG091G0L04; -.
DR   PhylomeDB; Q92793; -.
DR   TreeFam; TF101097; -.
DR   Reactome; R-HSA-1234158; Regulation of gene expression by Hypoxia-inducible Factor.
DR   Reactome; R-HSA-1368082; RORA activates gene expression.
DR   Reactome; R-HSA-1368108; BMAL1:CLOCK,NPAS2 activates circadian gene expression.
DR   Reactome; R-HSA-1912408; Pre-NOTCH Transcription and Translation.
DR   Reactome; R-HSA-1989781; PPARA activates gene expression.
DR   Reactome; R-HSA-201722; Formation of the beta-catenin:TCF transactivating complex.
DR   Reactome; R-HSA-2032785; YAP1- and WWTR1 (TAZ)-stimulated gene expression.
DR   Reactome; R-HSA-2122947; NOTCH1 Intracellular Domain Regulates Transcription.
DR   Reactome; R-HSA-2151201; Transcriptional activation of mitochondrial biogenesis.
DR   Reactome; R-HSA-2426168; Activation of gene expression by SREBF (SREBP).
DR   Reactome; R-HSA-2644606; Constitutive Signaling by NOTCH1 PEST Domain Mutants.
DR   Reactome; R-HSA-2894862; Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants.
DR   Reactome; R-HSA-3134973; LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production.
DR   Reactome; R-HSA-3214847; HATs acetylate histones.
DR   Reactome; R-HSA-3371568; Attenuation phase.
DR   Reactome; R-HSA-350054; Notch-HLH transcription pathway.
DR   Reactome; R-HSA-381340; Transcriptional regulation of white adipocyte differentiation.
DR   Reactome; R-HSA-400206; Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha).
DR   Reactome; R-HSA-400253; Circadian Clock.
DR   Reactome; R-HSA-5617472; Activation of anterior HOX genes in hindbrain development during early embryogenesis.
DR   Reactome; R-HSA-5621575; CD209 (DC-SIGN) signaling.
DR   Reactome; R-HSA-6803204; TP53 Regulates Transcription of Genes Involved in Cytochrome C Release.
DR   Reactome; R-HSA-8866907; Activation of the TFAP2 (AP-2) family of transcription factors.
DR   Reactome; R-HSA-918233; TRAF3-dependent IRF activation pathway.
DR   Reactome; R-HSA-933541; TRAF6 mediated IRF7 activation.
DR   Reactome; R-HSA-983231; Factors involved in megakaryocyte development and platelet production.
DR   SignaLink; Q92793; -.
DR   SIGNOR; Q92793; -.
DR   ChiTaRS; CREBBP; human.
DR   EvolutionaryTrace; Q92793; -.
DR   GeneWiki; CREB-binding_protein; -.
DR   GenomeRNAi; 1387; -.
DR   PRO; PR:Q92793; -.
DR   Proteomes; UP000005640; Chromosome 16.
DR   Bgee; ENSG00000005339; -.
DR   CleanEx; HS_CREBBP; -.
DR   ExpressionAtlas; Q92793; baseline and differential.
DR   Genevisible; Q92793; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0000123; C:histone acetyltransferase complex; IEA:InterPro.
DR   GO; GO:0016604; C:nuclear body; IDA:UniProtKB.
DR   GO; GO:0000790; C:nuclear chromatin; IDA:BHF-UCL.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0016407; F:acetyltransferase activity; IDA:UniProtKB.
DR   GO; GO:0003682; F:chromatin binding; IDA:UniProtKB.
DR   GO; GO:0000987; F:core promoter proximal region sequence-specific DNA binding; IDA:BHF-UCL.
DR   GO; GO:0003684; F:damaged DNA binding; IDA:UniProtKB.
DR   GO; GO:0004402; F:histone acetyltransferase activity; IDA:UniProtKB.
DR   GO; GO:0043426; F:MRF binding; IDA:UniProtKB.
DR   GO; GO:0002039; F:p53 binding; IPI:UniProtKB.
DR   GO; GO:0034212; F:peptide N-acetyltransferase activity; TAS:Reactome.
DR   GO; GO:0001102; F:RNA polymerase II activating transcription factor binding; TAS:BHF-UCL.
DR   GO; GO:0001105; F:RNA polymerase II transcription coactivator activity; TAS:BHF-UCL.
DR   GO; GO:0001085; F:RNA polymerase II transcription factor binding; IPI:BHF-UCL.
DR   GO; GO:0004871; F:signal transducer activity; TAS:ProtInc.
DR   GO; GO:0003713; F:transcription coactivator activity; IDA:UniProtKB.
DR   GO; GO:0003700; F:transcription factor activity, sequence-specific DNA binding; TAS:ProtInc.
DR   GO; GO:0008134; F:transcription factor binding; IPI:UniProtKB.
DR   GO; GO:0001078; F:transcriptional repressor activity, RNA polymerase II core promoter proximal region sequence-specific binding; IDA:BHF-UCL.
DR   GO; GO:0001191; F:transcriptional repressor activity, RNA polymerase II transcription factor binding; IDA:BHF-UCL.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:1904837; P:beta-catenin-TCF complex assembly; TAS:Reactome.
DR   GO; GO:0044255; P:cellular lipid metabolic process; TAS:Reactome.
DR   GO; GO:0034644; P:cellular response to UV; IDA:UniProtKB.
DR   GO; GO:0042733; P:embryonic digit morphogenesis; TAS:BHF-UCL.
DR   GO; GO:0016573; P:histone acetylation; IDA:UniProtKB.
DR   GO; GO:0042592; P:homeostatic process; NAS:UniProtKB.
DR   GO; GO:0018076; P:N-terminal peptidyl-lysine acetylation; IDA:UniProtKB.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; IDA:BHF-UCL.
DR   GO; GO:0007219; P:Notch signaling pathway; TAS:Reactome.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; TAS:Reactome.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0032481; P:positive regulation of type I interferon production; TAS:Reactome.
DR   GO; GO:0006473; P:protein acetylation; IDA:UniProtKB.
DR   GO; GO:0006461; P:protein complex assembly; TAS:ProtInc.
DR   GO; GO:0042981; P:regulation of apoptotic process; TAS:Reactome.
DR   GO; GO:1900034; P:regulation of cellular response to heat; TAS:Reactome.
DR   GO; GO:0008589; P:regulation of smoothened signaling pathway; TAS:BHF-UCL.
DR   GO; GO:0061418; P:regulation of transcription from RNA polymerase II promoter in response to hypoxia; TAS:Reactome.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; IDA:HGNC.
DR   GO; GO:0001666; P:response to hypoxia; TAS:UniProtKB.
DR   GO; GO:0048511; P:rhythmic process; IEA:UniProtKB-KW.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0002223; P:stimulatory C-type lectin receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0006367; P:transcription initiation from RNA polymerase II promoter; TAS:Reactome.
DR   GO; GO:0016032; P:viral process; IEA:UniProtKB-KW.
DR   CDD; cd15802; RING_CBP-p300; 1.
DR   Gene3D; 1.10.1630.10; -; 1.
DR   Gene3D; 1.20.1020.10; -; 2.
DR   Gene3D; 1.20.920.10; -; 1.
DR   InterPro; IPR001487; Bromodomain.
DR   InterPro; IPR018359; Bromodomain_CS.
DR   InterPro; IPR031162; CBP_P300_HAT.
DR   InterPro; IPR013178; Histone_AcTrfase_Rtt109/CBP.
DR   InterPro; IPR003101; KIX_dom.
DR   InterPro; IPR009110; Nuc_rcpt_coact.
DR   InterPro; IPR014744; Nuc_rcpt_coact_CREBbp.
DR   InterPro; IPR010303; RING_CBP-p300.
DR   InterPro; IPR000197; Znf_TAZ.
DR   InterPro; IPR000433; Znf_ZZ.
DR   Pfam; PF00439; Bromodomain; 1.
DR   Pfam; PF09030; Creb_binding; 1.
DR   Pfam; PF06001; DUF902; 1.
DR   Pfam; PF08214; HAT_KAT11; 1.
DR   Pfam; PF02172; KIX; 1.
DR   Pfam; PF02135; zf-TAZ; 2.
DR   Pfam; PF00569; ZZ; 1.
DR   PRINTS; PR00503; BROMODOMAIN.
DR   SMART; SM00297; BROMO; 1.
DR   SMART; SM01250; KAT11; 1.
DR   SMART; SM00551; ZnF_TAZ; 2.
DR   SMART; SM00291; ZnF_ZZ; 1.
DR   SUPFAM; SSF47040; SSF47040; 1.
DR   SUPFAM; SSF47370; SSF47370; 1.
DR   SUPFAM; SSF57933; SSF57933; 2.
DR   SUPFAM; SSF69125; SSF69125; 1.
DR   PROSITE; PS00633; BROMODOMAIN_1; 1.
DR   PROSITE; PS50014; BROMODOMAIN_2; 1.
DR   PROSITE; PS51727; CBP_P300_HAT; 1.
DR   PROSITE; PS50952; KIX; 1.
DR   PROSITE; PS50134; ZF_TAZ; 2.
DR   PROSITE; PS01357; ZF_ZZ_1; 1.
DR   PROSITE; PS50135; ZF_ZZ_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Activator; Acyltransferase;
KW   Alternative splicing; Biological rhythms; Bromodomain;
KW   Chromosomal rearrangement; Complete proteome; Cytoplasm;
KW   Disease mutation; Host-virus interaction; Isopeptide bond;
KW   Metal-binding; Methylation; Nucleus; Phosphoprotein; Polymorphism;
KW   Reference proteome; Repeat; Transcription; Transcription regulation;
KW   Transferase; Ubl conjugation; Zinc; Zinc-finger.
FT   INIT_MET      1      1       Removed. {ECO:0000244|PubMed:19413330,
FT                                ECO:0000244|PubMed:22814378}.
FT   CHAIN         2   2442       CREB-binding protein.
FT                                /FTId=PRO_0000211190.
FT   DOMAIN      587    666       KIX. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00311}.
FT   DOMAIN     1103   1175       Bromo. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00035}.
FT   DOMAIN     1323   1700       CBP/p300-type HAT. {ECO:0000255|PROSITE-
FT                                ProRule:PRU01065}.
FT   ZN_FING     347    433       TAZ-type 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00203}.
FT   ZN_FING    1701   1744       ZZ-type. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00228}.
FT   ZN_FING    1765   1846       TAZ-type 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00203}.
FT   REGION      227    410       Interaction with SRCAP.
FT                                {ECO:0000269|PubMed:10347196}.
FT   REGION     1124   1170       Interaction with histone.
FT                                {ECO:0000269|PubMed:24361270}.
FT   REGION     1162   1180       Interaction with ASF1A.
FT                                {ECO:0000269|PubMed:24616510}.
FT   REGION     1433   1435       Interaction with histone.
FT                                {ECO:0000250|UniProtKB:Q09472}.
FT   REGION     1434   1436       Acetyl-CoA binding.
FT                                {ECO:0000250|UniProtKB:Q09472}.
FT   REGION     1446   1447       Acetyl-CoA binding.
FT                                {ECO:0000250|UniProtKB:Q09472}.
FT   REGION     1460   1891       Interaction with TRERF1.
FT                                {ECO:0000269|PubMed:11349124}.
FT   COMPBIAS   1061   1064       Poly-Glu.
FT   COMPBIAS   1199   1487       Cys/His-rich.
FT   COMPBIAS   1555   1562       Poly-Glu.
FT   COMPBIAS   1943   1948       Poly-Pro.
FT   COMPBIAS   1967   1970       Poly-Gln.
FT   COMPBIAS   2081   2085       Poly-Gln.
FT   COMPBIAS   2199   2216       Poly-Gln.
FT   COMPBIAS   2245   2248       Poly-Gln.
FT   COMPBIAS   2297   2300       Poly-Gln.
FT   METAL       363    363       Zinc 1. {ECO:0000250}.
FT   METAL       367    367       Zinc 1. {ECO:0000250}.
FT   METAL       380    380       Zinc 1. {ECO:0000250}.
FT   METAL       385    385       Zinc 1. {ECO:0000250}.
FT   METAL       394    394       Zinc 2. {ECO:0000250}.
FT   METAL       398    398       Zinc 2. {ECO:0000250}.
FT   METAL       404    404       Zinc 2. {ECO:0000250}.
FT   METAL       409    409       Zinc 2. {ECO:0000250}.
FT   METAL       418    418       Zinc 3. {ECO:0000250}.
FT   METAL       422    422       Zinc 3. {ECO:0000250}.
FT   METAL       427    427       Zinc 3. {ECO:0000250}.
FT   METAL       430    430       Zinc 3. {ECO:0000250}.
FT   BINDING    1493   1493       Acetyl-CoA; via carbonyl oxygen.
FT                                {ECO:0000250|UniProtKB:Q09472}.
FT   BINDING    1498   1498       Acetyl-CoA.
FT                                {ECO:0000250|UniProtKB:Q09472}.
FT   BINDING    1502   1502       Acetyl-CoA.
FT                                {ECO:0000250|UniProtKB:Q09472}.
FT   SITE         29     30       Breakpoint for translocation to form
FT                                KAT6B-CREBBP.
FT   SITE        266    267       Breakpoint for translocation to form
FT                                KAT6A-CREBBP.
FT   MOD_RES       2      2       N-acetylalanine.
FT                                {ECO:0000244|PubMed:19413330,
FT                                ECO:0000244|PubMed:22814378}.
FT   MOD_RES     121    121       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:20068231}.
FT   MOD_RES     220    220       Omega-N-methylarginine.
FT                                {ECO:0000244|PubMed:24129315}.
FT   MOD_RES     601    601       Omega-N-methylated arginine.
FT                                {ECO:0000250}.
FT   MOD_RES     625    625       Omega-N-methylated arginine.
FT                                {ECO:0000250}.
FT   MOD_RES     657    657       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:P45481}.
FT   MOD_RES    1014   1014       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES    1030   1030       Phosphoserine.
FT                                {ECO:0000244|PubMed:17525332}.
FT   MOD_RES    1076   1076       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1216   1216       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES    1382   1382       Phosphoserine; by IKKA.
FT                                {ECO:0000269|PubMed:17434128}.
FT   MOD_RES    1386   1386       Phosphoserine; by IKKA.
FT                                {ECO:0000269|PubMed:17434128}.
FT   MOD_RES    1583   1583       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES    1591   1591       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES    1592   1592       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES    1595   1595       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES    1597   1597       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES    1741   1741       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES    1744   1744       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES    1763   1763       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    2063   2063       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES    2076   2076       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES    2079   2079       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES    2351   2351       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P45481}.
FT   CROSSLNK    998    998       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO1).
FT                                {ECO:0000250|UniProtKB:P45481}.
FT   CROSSLNK   1033   1033       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO1).
FT                                {ECO:0000250|UniProtKB:P45481}.
FT   CROSSLNK   1056   1056       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO1).
FT                                {ECO:0000250|UniProtKB:P45481}.
FT   VAR_SEQ     406    444       VAHCASSRQIISHWKNCTRHDCPVCLPLKNASDKRNQQT
FT                                -> A (in isoform 2). {ECO:0000303|Ref.4}.
FT                                /FTId=VSP_045700.
FT   VARIANT     503    503       Q -> H (in dbSNP:rs748447855).
FT                                {ECO:0000269|PubMed:25388907}.
FT                                /FTId=VAR_072912.
FT   VARIANT     532    532       P -> T. {ECO:0000269|PubMed:25388907}.
FT                                /FTId=VAR_072913.
FT   VARIANT     546    546       I -> N. {ECO:0000269|PubMed:25388907}.
FT                                /FTId=VAR_072914.
FT   VARIANT     650    650       Y -> F (in RSTS1).
FT                                {ECO:0000269|PubMed:25388907}.
FT                                /FTId=VAR_072915.
FT   VARIANT     789    789       A -> T (in RSTS1; dbSNP:rs746728741).
FT                                {ECO:0000269|PubMed:25388907}.
FT                                /FTId=VAR_072916.
FT   VARIANT     910    910       T -> A (in RSTS1; incomplete;
FT                                dbSNP:rs143247685).
FT                                {ECO:0000269|PubMed:20684013}.
FT                                /FTId=VAR_072917.
FT   VARIANT    1175   1175       Y -> C (in RSTS1; mild form; impairs
FT                                binding to ASF1A and acetylated histone
FT                                H3; dbSNP:rs28937315).
FT                                {ECO:0000269|PubMed:12114483,
FT                                ECO:0000269|PubMed:24616510,
FT                                ECO:0000269|PubMed:25388907}.
FT                                /FTId=VAR_037305.
FT   VARIANT    1278   1278       E -> A (in RSTS1).
FT                                {ECO:0000269|PubMed:25388907}.
FT                                /FTId=VAR_072918.
FT   VARIANT    1278   1278       E -> K (in RSTS1; abolishes
FT                                acetyltransferase activity;
FT                                dbSNP:rs267606752).
FT                                {ECO:0000269|PubMed:12566391,
FT                                ECO:0000269|PubMed:15706485}.
FT                                /FTId=VAR_035080.
FT   VARIANT    1378   1378       R -> P (in RSTS1; abolishes
FT                                acetyltransferase activity and the
FT                                ability of transactivate CREB;
FT                                dbSNP:rs121434626).
FT                                {ECO:0000269|PubMed:11331617,
FT                                ECO:0000269|PubMed:25388907}.
FT                                /FTId=VAR_015578.
FT   VARIANT    1406   1406       D -> Y (in RSTS1).
FT                                {ECO:0000269|PubMed:25388907}.
FT                                /FTId=VAR_072919.
FT   VARIANT    1414   1414       V -> I (in dbSNP:rs130015).
FT                                /FTId=VAR_027953.
FT   VARIANT    1415   1415       Q -> P (in RSTS1).
FT                                {ECO:0000269|PubMed:25388907}.
FT                                /FTId=VAR_072920.
FT   VARIANT    1447   1447       T -> I (in RSTS1).
FT                                {ECO:0000269|PubMed:15706485}.
FT                                /FTId=VAR_035081.
FT   VARIANT    1450   1450       Y -> H (in RSTS1).
FT                                {ECO:0000269|PubMed:15706485}.
FT                                /FTId=VAR_035082.
FT   VARIANT    1470   1470       H -> R (in RSTS1; dbSNP:rs797044860).
FT                                {ECO:0000269|PubMed:15706485}.
FT                                /FTId=VAR_035083.
FT   VARIANT    1475   1475       P -> T (in RSTS1).
FT                                {ECO:0000269|PubMed:25388907}.
FT                                /FTId=VAR_072921.
FT   VARIANT    1503   1503       Y -> F (in RSTS1).
FT                                {ECO:0000269|PubMed:25388907}.
FT                                /FTId=VAR_072922.
FT   VARIANT    1507   1507       L -> P (in RSTS1).
FT                                {ECO:0000269|PubMed:25388907}.
FT                                /FTId=VAR_072923.
FT   VARIANT    1543   1543       D -> N (in RSTS1).
FT                                {ECO:0000269|PubMed:25388907}.
FT                                /FTId=VAR_072924.
FT   VARIANT    1664   1664       R -> H (in RSTS1; abolishes
FT                                acetyltransferase activity).
FT                                {ECO:0000269|PubMed:12566391,
FT                                ECO:0000269|PubMed:15706485}.
FT                                /FTId=VAR_035084.
FT   MUTAGEN    1116   1116       D->R: Impairs binding to acetylated
FT                                histones. {ECO:0000269|PubMed:24616510}.
FT   MUTAGEN    1126   1126       F->A: Impairs binding to acetylated
FT                                histones. {ECO:0000269|PubMed:24616510}.
FT   MUTAGEN    1162   1162       N->E,R: Abolishes interaction with ASF1A.
FT                                {ECO:0000269|PubMed:24616510}.
FT   MUTAGEN    1165   1165       W->A: Abolishes interaction with ASF1A.
FT                                {ECO:0000269|PubMed:24616510}.
FT   MUTAGEN    1170   1170       K->E: Impairs binding to acetylated
FT                                histones. {ECO:0000269|PubMed:24616510}.
FT   MUTAGEN    1179   1179       S->I: Impairs interaction with ASF1A.
FT                                {ECO:0000269|PubMed:24616510}.
FT   MUTAGEN    1180   1180       K->E: Abolishes interaction with ASF1A.
FT                                {ECO:0000269|PubMed:24616510}.
FT   MUTAGEN    1183   1183       E->R: Abolishes interaction with ASF1A.
FT                                {ECO:0000269|PubMed:24616510}.
FT   CONFLICT   1511   1513       FAE -> NSG (in Ref. 2; AAC51340).
FT                                {ECO:0000305}.
FT   CONFLICT   1724   1725       ED -> VV (in Ref. 2; AAC51340).
FT                                {ECO:0000305}.
FT   CONFLICT   1770   1770       L -> V (in Ref. 1; AAC51770).
FT                                {ECO:0000305}.
FT   CONFLICT   1789   1789       N -> F (in Ref. 2; AAC51340).
FT                                {ECO:0000305}.
FT   CONFLICT   1812   1812       T -> P (in Ref. 2; AAC51340).
FT                                {ECO:0000305}.
FT   HELIX        69     73       {ECO:0000244|PDB:1RDT}.
FT   HELIX       377    379       {ECO:0000244|PDB:1LIQ}.
FT   TURN        383    388       {ECO:0000244|PDB:1LIQ}.
FT   HELIX       391    395       {ECO:0000244|PDB:1LIQ}.
FT   TURN        593    596       {ECO:0000244|PDB:2KWF}.
FT   HELIX       598    612       {ECO:0000244|PDB:2KWF}.
FT   TURN        618    622       {ECO:0000244|PDB:2KWF}.
FT   HELIX       624    642       {ECO:0000244|PDB:2KWF}.
FT   HELIX       647    669       {ECO:0000244|PDB:2KWF}.
FT   TURN        670    672       {ECO:0000244|PDB:2KWF}.
FT   HELIX      1087   1102       {ECO:0000244|PDB:5I86}.
FT   TURN       1105   1108       {ECO:0000244|PDB:5I86}.
FT   HELIX      1109   1111       {ECO:0000244|PDB:5I86}.
FT   HELIX      1117   1120       {ECO:0000244|PDB:5I86}.
FT   HELIX      1125   1128       {ECO:0000244|PDB:5I86}.
FT   HELIX      1135   1143       {ECO:0000244|PDB:5I86}.
FT   STRAND     1146   1149       {ECO:0000244|PDB:2L85}.
FT   HELIX      1150   1167       {ECO:0000244|PDB:5I86}.
FT   TURN       1169   1171       {ECO:0000244|PDB:1JSP}.
FT   HELIX      1173   1195       {ECO:0000244|PDB:5I86}.
FT   STRAND     1214   1218       {ECO:0000244|PDB:5I8G}.
FT   STRAND     1226   1230       {ECO:0000244|PDB:5I8G}.
FT   TURN       1231   1233       {ECO:0000244|PDB:5I8G}.
FT   STRAND     1234   1237       {ECO:0000244|PDB:5I8G}.
FT   TURN       1238   1240       {ECO:0000244|PDB:5I8G}.
FT   STRAND     1266   1272       {ECO:0000244|PDB:5I8G}.
FT   STRAND     1280   1282       {ECO:0000244|PDB:5I8G}.
FT   TURN       1284   1286       {ECO:0000244|PDB:5I8G}.
FT   STRAND     1289   1291       {ECO:0000244|PDB:5I8G}.
FT   HELIX      1292   1295       {ECO:0000244|PDB:5I8G}.
FT   TURN       1309   1311       {ECO:0000244|PDB:5I8G}.
FT   TURN       1708   1710       {ECO:0000244|PDB:2N1A}.
FT   STRAND     1718   1721       {ECO:0000244|PDB:2N1A}.
FT   STRAND     1725   1728       {ECO:0000244|PDB:2N1A}.
FT   HELIX      1730   1736       {ECO:0000244|PDB:2N1A}.
FT   STRAND     1742   1744       {ECO:0000244|PDB:2N1A}.
FT   HELIX      1765   1784       {ECO:0000244|PDB:2KJE}.
FT   HELIX      1793   1805       {ECO:0000244|PDB:2KJE}.
FT   TURN       1811   1815       {ECO:0000244|PDB:2KJE}.
FT   HELIX      1817   1832       {ECO:0000244|PDB:2KJE}.
FT   HELIX      1841   1853       {ECO:0000244|PDB:2KJE}.
FT   HELIX      2066   2072       {ECO:0000244|PDB:1ZOQ}.
FT   HELIX      2080   2091       {ECO:0000244|PDB:1ZOQ}.
FT   HELIX      2094   2103       {ECO:0000244|PDB:1ZOQ}.
FT   TURN       2104   2106       {ECO:0000244|PDB:1ZOQ}.
SQ   SEQUENCE   2442 AA;  265351 MW;  3BEA9B8558BA1A5E CRC64;
     MAENLLDGPP NPKRAKLSSP GFSANDSTDF GSLFDLENDL PDELIPNGGE LGLLNSGNLV
     PDAASKHKQL SELLRGGSGS SINPGIGNVS ASSPVQQGLG GQAQGQPNSA NMASLSAMGK
     SPLSQGDSSA PSLPKQAAST SGPTPAASQA LNPQAQKQVG LATSSPATSQ TGPGICMNAN
     FNQTHPGLLN SNSGHSLINQ ASQGQAQVMN GSLGAAGRGR GAGMPYPTPA MQGASSSVLA
     ETLTQVSPQM TGHAGLNTAQ AGGMAKMGIT GNTSPFGQPF SQAGGQPMGA TGVNPQLASK
     QSMVNSLPTF PTDIKNTSVT NVPNMSQMQT SVGIVPTQAI ATGPTADPEK RKLIQQQLVL
     LLHAHKCQRR EQANGEVRAC SLPHCRTMKN VLNHMTHCQA GKACQVAHCA SSRQIISHWK
     NCTRHDCPVC LPLKNASDKR NQQTILGSPA SGIQNTIGSV GTGQQNATSL SNPNPIDPSS
     MQRAYAALGL PYMNQPQTQL QPQVPGQQPA QPQTHQQMRT LNPLGNNPMN IPAGGITTDQ
     QPPNLISESA LPTSLGATNP LMNDGSNSGN IGTLSTIPTA APPSSTGVRK GWHEHVTQDL
     RSHLVHKLVQ AIFPTPDPAA LKDRRMENLV AYAKKVEGDM YESANSRDEY YHLLAEKIYK
     IQKELEEKRR SRLHKQGILG NQPALPAPGA QPPVIPQAQP VRPPNGPLSL PVNRMQVSQG
     MNSFNPMSLG NVQLPQAPMG PRAASPMNHS VQMNSMGSVP GMAISPSRMP QPPNMMGAHT
     NNMMAQAPAQ SQFLPQNQFP SSSGAMSVGM GQPPAQTGVS QGQVPGAALP NPLNMLGPQA
     SQLPCPPVTQ SPLHPTPPPA STAAGMPSLQ HTTPPGMTPP QPAAPTQPST PVSSSGQTPT
     PTPGSVPSAT QTQSTPTVQA AAQAQVTPQP QTPVQPPSVA TPQSSQQQPT PVHAQPPGTP
     LSQAAASIDN RVPTPSSVAS AETNSQQPGP DVPVLEMKTE TQAEDTEPDP GESKGEPRSE
     MMEEDLQGAS QVKEETDIAE QKSEPMEVDE KKPEVKVEVK EEEESSSNGT ASQSTSPSQP
     RKKIFKPEEL RQALMPTLEA LYRQDPESLP FRQPVDPQLL GIPDYFDIVK NPMDLSTIKR
     KLDTGQYQEP WQYVDDVWLM FNNAWLYNRK TSRVYKFCSK LAEVFEQEID PVMQSLGYCC
     GRKYEFSPQT LCCYGKQLCT IPRDAAYYSY QNRYHFCEKC FTEIQGENVT LGDDPSQPQT
     TISKDQFEKK KNDTLDPEPF VDCKECGRKM HQICVLHYDI IWPSGFVCDN CLKKTGRPRK
     ENKFSAKRLQ TTRLGNHLED RVNKFLRRQN HPEAGEVFVR VVASSDKTVE VKPGMKSRFV
     DSGEMSESFP YRTKALFAFE EIDGVDVCFF GMHVQEYGSD CPPPNTRRVY ISYLDSIHFF
     RPRCLRTAVY HEILIGYLEY VKKLGYVTGH IWACPPSEGD DYIFHCHPPD QKIPKPKRLQ
     EWYKKMLDKA FAERIIHDYK DIFKQATEDR LTSAKELPYF EGDFWPNVLE ESIKELEQEE
     EERKKEESTA ASETTEGSQG DSKNAKKKNN KKTNKNKSSI SRANKKKPSM PNVSNDLSQK
     LYATMEKHKE VFFVIHLHAG PVINTLPPIV DPDPLLSCDL MDGRDAFLTL ARDKHWEFSS
     LRRSKWSTLC MLVELHTQGQ DRFVYTCNEC KHHVETRWHC TVCEDYDLCI NCYNTKSHAH
     KMVKWGLGLD DEGSSQGEPQ SKSPQESRRL SIQRCIQSLV HACQCRNANC SLPSCQKMKR
     VVQHTKGCKR KTNGGCPVCK QLIALCCYHA KHCQENKCPV PFCLNIKHKL RQQQIQHRLQ
     QAQLMRRRMA TMNTRNVPQQ SLPSPTSAPP GTPTQQPSTP QTPQPPAQPQ PSPVSMSPAG
     FPSVARTQPP TTVSTGKPTS QVPAPPPPAQ PPPAAVEAAR QIEREAQQQQ HLYRVNINNS
     MPPGRTGMGT PGSQMAPVSL NVPRPNQVSG PVMPSMPPGQ WQQAPLPQQQ PMPGLPRPVI
     SMQAQAAVAG PRMPSVQPPR SISPSALQDL LRTLKSPSSP QQQQQVLNIL KSNPQLMAAF
     IKQRTAKYVA NQPGMQPQPG LQSQPGMQPQ PGMHQQPSLQ NLNAMQAGVP RPGVPPQQQA
     MGGLNPQGQA LNIMNPGHNP NMASMNPQYR EMLRRQLLQQ QQQQQQQQQQ QQQQQQGSAG
     MAGGMAGHGQ FQQPQGPGGY PPAMQQQQRM QQHLPLQGSS MGQMAAQMGQ LGQMGQPGLG
     ADSTPNIQQA LQQRILQQQQ MKQQIGSPGQ PNPMSPQQHM LSGQPQASHL PGQQIATSLS
     NQVRSPAPVQ SPRPQSQPPH SSPSPRIQPQ PSPHHVSPQT GSPHPGLAVT MASSIDQGHL
     GNPEQSAMLP QLNTPSRSAL SSELSLVGDT TGDTLEKFVE GL
//
